SpringWorks Therapeutics Inc [SWTX] stock is trading at $44.72, down -0.47%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SWTX shares have gain 17.93% over the last week, with a monthly amount drifted -3.79%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SpringWorks Therapeutics Inc [NASDAQ: SWTX] stock has seen the most recent analyst activity on November 20, 2024, when Evercore ISI initiated its Outperform rating and assigned the stock a price target of $60. Previously, Guggenheim started tracking the stock with Buy rating on February 05, 2024, and set its price target to $75. On December 01, 2022, BofA Securities initiated with a Buy rating and assigned a price target of $45 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $101 on January 19, 2021. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $73 on October 29, 2020. Barclays started tracking with a Overweight rating for this stock on May 05, 2020, and assigned it a price target of $48. In a note dated March 19, 2020, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $40 to $60.
SpringWorks Therapeutics Inc [SWTX] stock has fluctuated between $28.21 and $62.00 over the past year. Currently, Wall Street analysts expect the stock to reach $78 within the next 12 months. SpringWorks Therapeutics Inc [NASDAQ: SWTX] shares were valued at $44.72 at the most recent close of the market. An investor can expect a potential return of 74.42% based on the average SWTX price forecast.
Analyzing the SWTX fundamentals
SpringWorks Therapeutics Inc [NASDAQ:SWTX] reported sales of 191.59M for the trailing twelve months, which represents a growth of 1029.96%. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -1.45%, Pretax Profit Margin comes in at -1.35%, and Net Profit Margin reading is -1.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.48 and Total Capital is -0.57. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.27 points at the first support level, and at 43.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.09, and for the 2nd resistance point, it is at 45.46.
Ratios To Look Out For
For context, SpringWorks Therapeutics Inc’s Current Ratio is 3.81. Further, the Quick Ratio stands at 3.70, while the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 17.50, the price to book ratio is 6.92.
Transactions by insiders
Recent insider trading involved Edris Badreddin, Chief Operating Officer, that happened on Mar 03 ’25 when 20000.0 shares were sold. Chief Executive Officer, Islam Saqib completed a deal on Mar 03 ’25 to sell 49000.0 shares. Meanwhile, Chief Executive Officer Islam Saqib sold 29328.0 shares on Feb 20 ’25.
